CN101284795B - Non-steroidal male hormone receptor regulating agent and medical uses thereof - Google Patents
Non-steroidal male hormone receptor regulating agent and medical uses thereof Download PDFInfo
- Publication number
- CN101284795B CN101284795B CN2007100392686A CN200710039268A CN101284795B CN 101284795 B CN101284795 B CN 101284795B CN 2007100392686 A CN2007100392686 A CN 2007100392686A CN 200710039268 A CN200710039268 A CN 200710039268A CN 101284795 B CN101284795 B CN 101284795B
- Authority
- CN
- China
- Prior art keywords
- acid
- compound
- disease
- androgen receptor
- male sex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003795 chemical substances by application Substances 0.000 title description 3
- 108091008039 hormone receptors Proteins 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 42
- 201000010099 disease Diseases 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 208000024891 symptom Diseases 0.000 claims abstract description 18
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 8
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 7
- 206010028289 Muscle atrophy Diseases 0.000 claims abstract description 6
- 201000000585 muscular atrophy Diseases 0.000 claims abstract description 6
- 239000003163 gonadal steroid hormone Substances 0.000 claims description 34
- 102000001307 androgen receptors Human genes 0.000 claims description 27
- 108010080146 androgen receptors Proteins 0.000 claims description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- -1 aryl sulfonic acid Chemical compound 0.000 claims description 6
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 5
- 206010034010 Parkinsonism Diseases 0.000 claims description 5
- 229940124011 Androgen receptor agonist Drugs 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 230000036299 sexual function Effects 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 abstract description 19
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 19
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract description 13
- 239000003098 androgen Substances 0.000 abstract description 12
- 201000004384 Alopecia Diseases 0.000 abstract description 10
- 230000001419 dependent effect Effects 0.000 abstract description 10
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 9
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 8
- 206010000496 acne Diseases 0.000 abstract description 8
- 231100000360 alopecia Toxicity 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000003637 steroidlike Effects 0.000 abstract description 7
- 206010020112 Hirsutism Diseases 0.000 abstract description 6
- 206010006187 Breast cancer Diseases 0.000 abstract description 5
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 5
- 206010002261 Androgen deficiency Diseases 0.000 abstract description 3
- 230000001568 sexual effect Effects 0.000 abstract description 3
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 239000000849 selective androgen receptor modulator Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 22
- 239000000243 solution Substances 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000000556 agonist Substances 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 230000003042 antagnostic effect Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 6
- 108700008625 Reporter Genes Proteins 0.000 description 6
- 230000008485 antagonism Effects 0.000 description 6
- 229960000997 bicalutamide Drugs 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 239000000051 antiandrogen Substances 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 206010025482 malaise Diseases 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 4
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 4
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 229940061641 androsterone Drugs 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000009514 concussion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 3
- 229960002074 flutamide Drugs 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-M glutaminate Chemical compound [O-]C(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-M 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- CBMYJHIOYJEBSB-YSZCXEEOSA-N 5alpha-androstane-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 CBMYJHIOYJEBSB-YSZCXEEOSA-N 0.000 description 2
- 206010002027 Amyotrophy Diseases 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 244000207449 Prunus puddum Species 0.000 description 2
- 235000009226 Prunus puddum Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003936 androgen receptor antagonist Substances 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229960000978 cyproterone acetate Drugs 0.000 description 2
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- RZRPTBIGEANTGU-UHFFFAOYSA-N -Androst-4-ene-3,11,17-trione Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)=O)C4C3CCC2=C1 RZRPTBIGEANTGU-UHFFFAOYSA-N 0.000 description 1
- WYECURVXVYPVAT-UHFFFAOYSA-N 1-(4-bromophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Br)C=C1 WYECURVXVYPVAT-UHFFFAOYSA-N 0.000 description 1
- BUZYGTVTZYSBCU-UHFFFAOYSA-N 1-(4-chlorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C=C1 BUZYGTVTZYSBCU-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010069921 Anti-androgen withdrawal syndrome Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010057671 Female sexual dysfunction Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- RZRPTBIGEANTGU-IRIMSJTPSA-N adrenosterone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 RZRPTBIGEANTGU-IRIMSJTPSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000009165 androgen replacement therapy Methods 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical group OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229950004783 cipionate Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000001752 female genitalia Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000022182 gross hematuria Diseases 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 210000000260 male genitalia Anatomy 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 230000005184 men's health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229960000270 methylestrenolone Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
- C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明所涉及的一类具有通式I结构的非甾体类雄激素受体调节剂或其药学上可接受的盐，是可用于制备预防和/或治疗中老年男性雄激素部分缺乏综合征、骨质疏松症、肌消耗、女性性功能不全、厌食、女性多毛症、重度雄激素依赖型脱发、痤疮、恶质病、良性前列腺增生、前列腺癌、乳腺癌、阿尔茨海默病和帕金森综合症等的非甾体类药物的化合物。本发明还涉及包含通式I化合物或其药学上可接受的盐的药物组合物，以及通式I化合物或其药学上可接受的盐在制备用于治疗上述症状或疾病的药物中的用途。 The present invention relates to a class of non-steroidal androgen receptor modulators with a general formula I structure or pharmaceutically acceptable salts thereof, which can be used to prepare and prevent and/or treat middle-aged and elderly male partial androgen deficiency syndrome , osteoporosis, muscle wasting, female sexual insufficiency, anorexia, female hirsutism, severe androgen-dependent alopecia, acne, cachexia, benign prostatic hyperplasia, prostate cancer, breast cancer, Alzheimer's disease, and Pa Compounds of non-steroidal drugs for Kinson's syndrome, etc. The present invention also relates to a pharmaceutical composition comprising the compound of general formula I or a pharmaceutically acceptable salt thereof, and the use of the compound of general formula I or a pharmaceutically acceptable salt thereof in the preparation of medicines for treating the above-mentioned symptoms or diseases. 
Description
Technical field
The present invention relates to class I non-steroid androgen acceptor regulator and pharmaceutical composition thereof and preventing and/or treating symptom that male sex hormone and androgen receptor functional disorder cause or the purposes in the disease medicament; Include, but are not limited to that the middle-aging male male sex hormone lacks partly that syndrome, osteoporosis, muscle wasting (Sarcopenia), femal sexual function are complete, apocleisis, female hirsutism, the alopecia of severe male sex hormone dependent form, acne, evil matter disease, benign prostatic hyperplasia, prostate cancer, mammary cancer, alzheimer's disease (Alzheimer ' s disease; AD) and parkinsonism (Parkinson ' s disease, PD) etc.
Background technology
Male sex hormone (Androgen) is one type of important steroidal class sexual hormoue in the human body; Through with androgen receptor (Androgen Receptor; AR) combine to promote cytodifferentiation and tissue growth, participate in numerous crucial physiological functions such as male fetus reproductive organ (like prostate gland, seminal vesicle, epididymis etc.) formation, secondal sexual character growth with keep and sperm generation etc.All have a certain proportion of male sex hormone in the sex body, as androsterone (Testosterone, T), (Dihydrotestosterone is DHT) with adrenosterone etc. for androstanediol.In female body, androsterone can change oestrogenic hormon in most of target organ, but the physiological function of in portion of tissue such as brain, bringing into normal play.In prostate gland and skin, androsterone is converted into DHT by 5, and compares with T, and DHT will exceed 3-5 times to the avidity of AR.
AR is a member of nuclear receptor superfamily; Metal ligand activated transcription factor; Be distributed widely in propagation and non-propagation tissue; Comprise prostate gland and seminal vesicle, male and female genital organ, testis, ovary, skin, hair follicle, sweat gland, cartilage, cardiac muscle, bone and unstriated muscle, adrenal cortex, liver, pineal gland and a plurality of palliumes district and cortex inferior segment, comprise dynamoneure (Negro-Vilar, J Clinical Endocrinology and Metabolism; 1999,84:3459-3462).AR albumen has three structural domains: N end structure territory (N terminal domain; NTD), DNA combines territory (DNA binding domain; DBD) and ligand binding domain (Ligandbinding domain, LBD) (He B, Kemppainen JA; 1999, J.Biol.Chem.274:37219-25).After the LBD of male sex hormone and AR formed mixture, (Androgen response element ARE) combined, and plays the effect that activates or suppress expression of target gene, thereby regulates and control the physiological function of target tissue to reply original paper with the male sex hormone that is positioned at the target gene promoters district.The generation of a lot of AR relative diseases, or because hormonal readiness is not normal, or, destroyed normal interaction equilibrium relationship because function of receptors is disorderly.In diseased individuals, medicine can reach the effect of treating relative disease through strengthening or suppressing the receptor activation level.Therefore, in the middle of the treatment multiple disease and symptom relevant with androgenic effect, AR is important target.For metabolism and incretion disease; The AR regulator can be used for preventing/treating and age and male hormone metabolism diseases associated, as the elderly men male sex hormone reduce that disease, women's hypoandrogenism disease, osteoporosis, muscle wasting, femal sexual function are complete, evil matter disease when apocleisis, hirsutism, the alopecia of severe male sex hormone dependent form, acne, several morbid state etc.In oncology, the AR regulator can be used for treating benign prostatic hyperplasia, hormonal dependent prostate cancer and mammary cancer etc.; For nervous system disorders, the AR regulator can be used for treating melancholia, presenile dementia and parkinsonism etc. (Segal S., Naraynan R.and Dalton J.Expert Opin.Investig.Drugs2006,15:377-387).
Clinical AR regulator commonly used is divided into steroidal class and nonsteroidal from structure.Steroidal class male sex hormone in body natural generation; The ester (like cipionate, propionic ester, phenylpropionic acid ester, cyclopentanepropanoiacid acid ester, heptanoate and decylate) that also comprises androsterone, and other synthetic type male sex hormone (like 7-methylnortestosterone and acetic ester thereof).Then (Cyproterone acetate CPA) is representative to androgen antagonist with cyproterone acetate.Nonsteroidal AR regulator is used more have flutamide (Flutamide), RU-23908 (Nilutamide) and bicalutamide, and (Bicalutamide Casodex) etc., is receptor antagonist.Document and patent report have also the been arranged AR agonist of some non-steroidals, but all do not get into clinical application at present.Be that steroidal and nonsteroidal AR regulator all have certain spinoff, comprise causing the estrogen and androgen metabolism disorder and making gynaecomastia and hepatotoxicity etc.Spinoffs such as hyperplasia of prostate/patients with prostate cancer people takes for a long time that flutamide or bicalutamide gastrointestinal discomfort can occur, feel sick, vomiting, insomnia, weak, headache, anxiety, blurred vision and hyposexuality; And " androgen antagonist go down syndromes " (Antiandrogen withdrawalsyndrome can appear in single taking behind certain androgen antagonist medicine; AWS); Rising rapidly, gross tumor volume increase the repressed PSA level of script again after showing as medication for some time; Can only withdrawal or migrate other androgen antagonist medicines (DickerAP, 2003, Lancet Oncol.4:30-36; Laufer M, Sinibaldi VJ, 1999, Urology54:745].There is report to show that there is interaction in the AR regulator with the antithrombotics tonka bean camphor in use in addition.Therefore, press for the nonsteroidal AR regulator that research and development has brand-new chemical structure clinically.
Researchist of the present invention discloses class I non-steroid androgen acceptor regulator and preparation method thereof, pharmaceutical composition and purposes in the CN200510026252.2 patented claim.Though in purposes, disclose the effect that this compounds has androgen receptor modifier, only disclose the purposes of compound, and its purposes as the androgen receptor agonist aspect is not done any elaboration as androgen receptor antagonists.
Summary of the invention
The defective that exists to above-mentioned prior art or not enough, the present invention is through chemosynthesis and structure activity study, prepares and optimized one type of novel nonsteroidal micromolecular compound.Androgen receptor competition combines experiment to show, this compounds to the avidity of acceptor less than 10nM, suitable with DHT; Luciferase reporter gene cotransfection experiments and prostate cancer cell strain LNCaP proliferation experiment show that it has excitement of AR part and antagonistic activity, has showed the potentiality that are developed further into to novel androgen receptor modifier.
Therefore, the object of the present invention is to provide one type of Nonsteroic androgen acceptor regulators compound or its pharmacy acceptable salt with following general formula I structure.
Another purpose of the present invention is to provide the compound that comprises the general formula I structure or the pharmaceutical composition of its pharmacy acceptable salt.
Compound or its pharmacy acceptable salt that a purpose more of the present invention is to provide the general formula I structure as the nonsteroidal androgen receptor modifier in the preparation prevention or/and symptom that treatment causes because of male sex hormone and androgen receptor functional disorder or the purposes in the disease.
Compound with general formula I structure of the present invention or its pharmacy acceptable salt as the nonsteroidal androgen receptor agonist in the preparation prevention or/and symptom that treatment causes because of male sex hormone and androgen receptor functional disorder or the purposes in the disease.
Compound with general formula I structure of the present invention or its pharmacy acceptable salt as the nonsteroidal androgen receptor antagonists in the preparation prevention or/and symptom that treatment causes because of male sex hormone and androgen receptor functional disorder or the purposes in the disease.
Nonsteroic androgen acceptor regulators provided by the invention or its pharmacy acceptable salt have the structure of following general formula I:
Wherein: R is Cl or Br; Specific examples is compound 3-phenyl-3-(4-oil of mirbane amido)-1-(4-chloro-phenyl-)-1-acetone (MWW6003) and 3-phenyl-3-(4-oil of mirbane amido)-1-(4-bromophenyl)-1-acetone (MWW6015), and its structural formula is following:
For compound or its pharmacy acceptable salt of general formula I structure of the present invention, when having chiral carbon in the molecule, it is raceme or optically active body.
The compound of general formula I structure of the present invention can obtain acceptable salt on its pharmacology through conventional salifiable method pharmaceutically with any suitable acid, and for example, described acid is mineral acid, example hydrochloric acid, Hydrogen bromide, nitric acid, sulfuric acid, phosphoric acid etc.; Organic acid is such as formic acid, acetate, propionic acid, phenylformic acid, toxilic acid, fumaric acid, succsinic acid, tartrate, Hydrocerol A etc.; Alkylsulphonic acid is like methylsulphonic acid, ethylsulfonic acid etc.; Aryl sulfonic acid all can use like Phenylsulfonic acid, tosic acid etc.
Pharmaceutical composition provided by the invention comprises compound or its pharmacy acceptable salt of one or more general formula I structures of treating significant quantity, and this pharmaceutical composition can further contain one or more pharmaceutically acceptable carrier or vehicle.
Its ideal ratio of pharmaceutical composition provided by the present invention is, compound of Formula I or its pharmacy acceptable salt account for gross weight than 50%～99.5% as activeconstituents, and rest part accounts for gross weight than below 50%.
A purpose more of the present invention provides through giving androgen receptor modifier as herein described or its pharmacy acceptable salt (comprising its pharmaceutical composition), prevent and/or treat the various symptoms that cause because of male sex hormone and androgen receptor functional disorder or the method for disease as androgen receptor agonist and/or antagonist, includes but not limited to that osteoporosis, muscle wasting, femal sexual function are complete, apocleisis, female hirsutism, the alopecia of severe male sex hormone dependent form, acne, stearrhea, evil matter sick (including but not limited to AIDS), benign prostatic hyperplasia, prostate cancer, androgenetic alopecia, the optimum or malignant tumour (for example occurring in the cancer of tissues such as mammary gland, brain, skin, ovary, bladder, lymph, liver, kidney and pancreas) of expression androgen receptor, endometriosis, polycystic ovary syndrome, Alzheimer, parkinsonism, androgen-dependent/age related disease (partly lacking the amyotrophy of syndrome, male or female sexual dysfunction and non-sickbed patients etc. like the middle-aging male male sex hormone).Be preferably applied to treatment/prevention androgen-dependent tumour, especially prostate cancer especially, reduce the sickness rate of prostate cancer, stop the generation of prostate cancer or cause prostate cancer to disappear.
Description of drawings
To be compound combine the vigor test with DHT to the competitiveness of AR to Fig. 1.Compound MWW6003 and MWW6015 are suitable to avidity and the DHT of AR, both IC
50Value is respectively 2.23 and 3.48nM, the IC of DHT under the similarity condition
50Be 7.75nM.
Fig. 2 is the cytotoxicity test of compound in the HeLa cell.After compound MWW6003 and MWW6015 and HeLa cell were hatched three days, with the influence of its cell growth of MTT method mensuration, both only showed low cytotoxicity, the wherein IC of compound MWW6003
50Value is 2.8 μ M, the IC of MWW6015
50Between 10～40 μ M.
Fig. 3 is the pharmacologically active test of compound in MDA-MB-453 cell reporter gene transfection experiment.Dihydrotestosterone (DHT) thus the expression of luciferase increases chemiluminescence readings in the inducing cell, compound shows as the antagonistic action of androgen receptor and suppresses the chemoluminescence of DHT inductive.MWW6003 and MWW6015 be display part AR agonist activity under activation pattern, and its usefulness is respectively 19.5% and 20.4% of DHT, EC
50Be respectively 320.1nM and 159.6nM, the EC of DHT under the similarity condition
50Be 0.6nM; Under the antagonism pattern, compound MWW6003 and MWW6015 have shown certain AR antagonistic activity, its IC
50Be respectively 884.8nM and 958.1nM, and bicalutamide (Bicalutamide, IC BCA) under the similarity condition
50Be 690.9nM.
Fig. 4 is the pharmacologically active test of compound in the LNCaP cell proliferation experiment.LNCaP is the hormonal dependent prostate cancer cell, and DHT and AR agonist all can be induced its propagation, and the AR antagonist can suppress DHT inductive cell propagation effect.The result shows that compound MWW6003 and MWW6015 all show certain activity trend under exciting and antagonism pattern.
Embodiment
In order to illustrate content of the present invention and not limited to by it, the present invention is divided into following trifle is described in detail.
Definition
Only if definition is arranged in addition, technology that the present invention is used and scientific term have same meaning with the general understanding of the current techique in field under the present invention.The application of all patents that derive from gene pool and other DBs that this place mentions, application, announcement and other publications and sequence are taken in comprehensively to be quoted as a reference.If the definition that the application of all patents that derive from gene pool and other DBs of definition that this joint is illustrated and this patent ginseng usefulness, application, announcement and other publications and sequence are taken in and quoted is set forth opposite; Or when inconsistent, the definition of illustrating with this joint is as the criterion.
Used herein, " one " or " one " refers to " at least one " or " one or more ".
Used herein; " regulator " refers to that one type can strengthen (like agonist; Have agonist activity) or suppress (like antagonist; Have antagonistic activity) biological activity of target protein (comprising enzyme, acceptor etc.) or the compound of function, and its strengthen only temporarily act on specific cells with restraining effect or organize in the generation of a certain particular event, like signal transduction, transcription activating etc.
Used herein; " the middle-aging male male sex hormone partly lacks syndrome " (Partial androgendeficiency of the aging male; PADAM) refer to the progressive minimizing that middle age back male sex's male sex hormone produces, clinical manifestation comprises fatigue, depression, sexual desire reduction, sexual dysfunction, erective dysfunction, hypogonadism, osteoporosis, alopecia, obesity, senile amyotrophy, osteopenia, benign prostatic hyperplasia, anaemia, mood and cognitive change and prostate cancer etc.The generation of PADAM is relevant with the male sex hormone environment also can be corrected through control male sex hormone environment.
Used herein, " osteoporosis " (Osteoporosis is a kind of skeletal diseases of general OP), it is characterized in that bone density is hanged down and the degeneration of osseous tissue, has increased the friability of bone and the susceptibility of fracture.Fracture of femur is result the most serious in the osteoporosis, has the patient of 5-20% dead in 1 year, and loses viability above 50% survivor.The elderly suffers from the dangerous maximum of osteoporosis, and its sickness rate significantly raises with aging population.In addition, the women has more the tendency of suffering from osteoporosis than the male sex.Male sex hormone and estrogenic physiological concentration play an important role to keeping the bone homeostasis in whole life.Therefore, when male sex hormone or oestrogenic hormon were lost, its result had increased the bony remodeling ratio, has made the balance that absorbs and form tend to absorb again, has promoted the total loss of bone amount.Suitably replenish male sex hormone and male sex hormone appearance material and help to increase bone density, improve osteoporosis, reduce the generation of fracture.
Used herein, " hyperplasia of prostate " refers to one type because of prostatic optimum adenomatoid hyperplasia around the urethra causes in various degree bladder outflow obstruction property disease or symptom, is also referred to as " benign prostatauxe ".Hyperplasia of prostate is one of modal disease of Urology Surgery, has become " the stealthy killer " that threaten men's health.Clinical statistics shows, the male sex during 40-79 year, after the sickness rate of benign prostate hyperplasia is about 50%, 80 years old then up to 80%.Along with rhythm of life is constantly accelerated, Benign Prostatic Hypertrophy day by day increases, and is rejuvenation trend.Benign prostatic hyperplasia also is prone to cause multiple potential complication, like AUR, urinary tract infection, gross hematuria, vesical diverticulum, calculus, uronephrosis and renal failure etc. in puzzlement patient daily life.Research shows that the intravital dihydrotestosterone of patient is the main inducement of benign prostatic hyperplasia, and the androgen antagonist treatment helps to improve its symptom.
Used herein, " prostate cancer " refers to one type of male reproductive system common malignancy, is main with gland cancer.Prostate cancer is a kind of serious male sex's geriatric disease, and is very high at the M & M of European and American areas, accounts for the first place ([Landis SH, Murray T, 1998, CA Cancer J.Clin.48:6-29] of male sex's malignant tumour.Though the sickness rate of China's prostate cancer is lower than American-European countries, in recent years along with the acceleration of aging population degree, the change of traditional food structure, and to the raising of this type medical diagnosis on disease level, sickness rate is remarkable growth situation.Can excision except that early prostate cancer, anti androgenic therapy be clinical preferred option.
Used herein; " hirsutism " refers to the crinosity symptom that one type of disease that increases because of 3male hormone secretion causes in the women; Many not only long not only thick but also black hairs have promptly been grown at the position that should not become mildewed; Perhaps hair is android type and distributes, the phenomenon of thick and heavy black, pubes ventrad of eyebrow even umbilical region development.
Used herein, " alopecia of severe male sex hormone dependent form " refers to one type of serious seborrheic alopecia, claims male pattern alopecia again.
Used herein, " acne " refers to one type of pilosebaceous chronic inflammatory diseases, and good sending out in face, thoracic dorsal shows as infringements such as acne, papule, warts, tubercle, tumour, claims acne of youth again.
Used herein; " Alzheimer " is one group of primary degeneration brain degenerative disease that the cause of disease is not bright, and pathological change is mainly the cortex diffuse atrophy, and ditch returns broadening; The ventricles of the brain enlarge; Neurone reduces in a large number, and it is thus clear that pathologies such as senile plaque, NFT, graininess cavity corpusculum, choline acetylase and acetyl choline content significantly reduce.The a lot of diseases of alzheimer's disease are in the senium, and latent disease is slowly irreversibly made progress (2 years or longer), is main with the intelligence infringement.Onset 65 years old with the former (pre-aged), have with sick family history more, pathological development is very fast, temporo page or leaf and top page or leaf pathology are more remarkable, and aphasia and appraxia are often arranged.In the experiment of one group of placebo; The cognitive disorder of patients with Alzheimer disease is improved after accepting androgen replacement therapy; Pointed out clinical value (Cherrier MM, Matsumoto AM, the Amory JK et al.2005 of androgen receptor in this disease; Neurology, 64:2063-2068).
Used herein, " Parkinson's disease " are central nervous system degenerative diseases common among the elderly, mainly show as patient motion slowly, other part of trick or health trembles, health loses flexibility, muscle rigidity.Parkinson's disease are only second to tumour and cardiovascular and cerebrovascular diseases to the harm of patient's viability, thereby are called as the elderly's " the 3rd killer ", " chronic cancer ".People such as Okun confirm male sex hormone be supplemented with help improve this sick symptom (Okun MS, Walter BL, Mcdonald WM, et al.2002, Arch.Neurol.59:1750-1753).
" significant quantity " that is used to treat the compound of a certain specified disease used herein refers to enough improve or alleviate to a certain extent the amount of the sick symptom that accompanies therewith.This dosage can the single dose administration, also can be according to the regimen administration.But this dosage cure diseases, but be typically administration in order to improve this symptom.Possibly need for improving the symptom repeat administration.
Used herein, " acceptable salt, ester or other verivates on the pharmacology " comprises any salt, ester or verivate that those skilled in the art are easy to prepare with currently known methods.The compound of deriving like this and generating can not have toxic action to animal and human's administration.This compound or have pharmaceutical activity, or prodrug.
Used herein, " treatment " refers to that disease and symptom are improved with any way, or other useful changes.Treatment also comprises the application of The compounds of this invention on medicine.
Used herein, the symptom that gives a certain specified disease of a certain specific medication compsn " improvement " is meant any alleviating, and is no matter permanent, interim, over a long time, of short duration, can both owing to or relevant with using of this pharmaceutical composition.
Used herein; " pure basically " is meant enough even; Can not survey impurity for estimating the standard method of analysis that purity uses by one of skill in the art, said standard method of analysis is just like thin layer chromatography (TLC), gel electrophoresis and HPLC (HPLC).Even perhaps enough pure also refer to be further purified can not change the observable physicochemical property of this material, for example enzymic activity and biological activity.Being used for purifying compounds and making chemical pure basically method, is known in those skilled in the art.Yet chemical pure basically compound can be the mixture of steric isomer or isomers.In this case, be further purified the specific activity that perhaps can increase compound.
Used herein, " prodrug " is meant a kind of compound of vivo medicine-feeding, and this compound can be by metabolism, or be converted into biologically, on the pharmacology or the activity form on the therapeutics.In order to make prodrug, pharmaceutical active compounds will be modified, and this active compound is produced through metabolic process again.Prodrug can be designed to change its metabolic stability, or the precursor of transportation characterization, to cover its spinoff or toxicity, improves the sense of taste of medicine, or changes other characteristics.Rely on the knowledge of pharmacokinetics and medicine internal metabolism, in case active compound is known on the pharmacology, those skilled in the art just can design the prodrug of this compound.[referring to Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, 1985, pages388-392].
Term " basically " is identical even or similar, can in context, change to some extent the understanding of correlation technique according to those skilled in the art, and be generally at least 70%, is preferably at least 80%, more excellently be at least 90%, and optimum is identical at least 95%.
Here used " compsn " refers to any mixture.Can be solution, suspension, liquid, powder, ointment, water-based, nonaqueous or their any combination.
Here used " associating " refers to any associating between two or more.
Term used herein " object " comprises humans and animals, for example, and dog, cat, ox, pig, rodent etc., preferred people.It is to be suitable for and to be ready the middle-aging male male sex hormone that is caused by male sex hormone and/or androgen receptor functional disorder or follow partly lacked diseases such as syndrome, osteoporosis, muscle wasting, apocleisis, female hirsutism, the alopecia of severe male sex hormone dependent form, acne, evil matter disease, benign prostatic hyperplasia, prostate cancer, mammary cancer, alzheimer's disease and parkinsonism and illness and to treat and prevent that experienced implementer should understand object.
Any protectiveness group used herein, the abbreviation of amino acid and other compounds, consistent with their abbreviations general, that generally acknowledge or the biochemical name of IUPAC-IUB council promulgation, unless stated otherwise.
Prescription and dosage
According to the present invention; Compound of the present invention is united separately or with other medicament, carrier or vehicle; For any suitable route of administration is formulated preparation, for example intracavitary administration, subcutaneous injection, intravenous injection, intramuscularly, intradermal are injected, oral or local application.Present method can be used injecting and administering preparations, with the form of single dose at ampoule, or in the multi-dose container with the buffer reagent drug administration by injection that adds.Preparation can be taked following form such as suspension, solution or the emulsion in oiliness or aqueous media.Preparation can contain prescription reagent such as suspensoid, stablizer and/or dispersion agent.In addition, before the use, activeconstituents can powder type and suitable carriers, aseptic no heat source water or other solvents formation formulation.Local application of the present invention can adopt foam, gel, and ointment, ointment changes leather diaphragm, or paste.
Operable medicinal compsns and the method that is used for administration includes, but are not limited among the present invention, USP 5,736,154,6,197; 801B1,5,741,511,5,886,039,5,941; 868,6,258,374B1 and 5,686,102 contents reported.
The dosage size of treatment or prevention due to illness the seriousness of feelings with route of administration and variation to some extent.Dosage can react different because of age, body weight, healthy state and individual patient with the medication frequency.
It is to be noted (the diagnosis and treatment doctor also should know), according to toxicity and side reaction, the termination of must taking the necessary measures, interruption or reduction therapeutic dose.On the contrary, if clinical response not obvious (getting rid of toxicity and side reaction), the doctor should suitably adjust regimen, improves dosage.
Any suitable route of administration all may be utilized.Formulation comprises tablet, lozenge, beans shape capsule, dispersion agent, suspension agent, solution, capsule, diaphragm and analogue etc.
In practical application, compound of the present invention is united separately or with other preparations, can be according to general pharmacology hybrid technology and pharmaceutical carrier or vehicle, and for example beta-cyclodextrin and 2-hydroxyl-propyl group-beta-cyclodextrin are closely mixed.According to the needs of dispensing, can adopt the special carrier of universal support, part or parenteral route.Prepare non-parenteral dosage forms, for example intravenous injection or the compsn inculcated can adopt similar medicine medium, water known in those skilled in the art, terepthaloyl moietie, oil, buffer reagent, sugar, sanitas, liposome etc.The example of this non-enteron aisle compsn comprises, but is not restricted to Vadex, saline water or other solution of 5%W/V.The total dose of compound of the present invention, separately or with other preparation administation of combination, the administration of available bottle intravenous fluid, volume is approximately from 1 milliliter to 2000 milliliters.According to the total dose of administration, the dilution liquid measure also can be different.
The present invention also provides the medicine box of realizing regimen.This medicine box is united the compound of the present invention of effective dose separately or with other reagent with acceptable form on the pharmacology, is included in one or more containers.Preferably medicament forms is and Sterile Saline, dextrose solution, and buffered soln, or other drug is learned upward, and acceptable sterile liquid share.Perhaps, compsn can be by freeze-drying or drying; In this case, medicine box is randomly further with acceptable solution on a kind of pharmacology, and preferred aseptic solution is included in the container, is formed for injecting the solution of purpose to reformulate mixture.Acceptable solution is salt brine solution and dextrose solution on the typical pharmacology.
In another embodiment, medicine box of the present invention further comprises and is used for the preferred with the pin of sterile form packing or the alcohol pads of syringe and/or packing of injectable composition.Can randomly comprise the specification sheets that supplies doctor or patient to use.
Below in conjunction with specific embodiment the present invention is done further elaboration, but do not limit the present invention.
Synthesizing of 3-phenyl-3-(4-oil of mirbane amido)-1-(4-chloro-phenyl-)-1-acetone (MWW6003)
Phenyl aldehyde 10.60 grams (0.1mol), 4-N-methyl-p-nitroaniline 13.81 grams (0.1mol), absolute ethyl alcohol 150ml are added in the reaction flask; After the stirring at room 10 minutes; Add the concentrated hydrochloric acid of 4-chloro-acetophenone 15.46 grams (0.1mol) and catalytic amount, the stirring at room reaction is 20 hours then.After reaction finishes, with the reaction solution cool overnight, the solid that suction filtration is separated out, and use absolute ethanol washing.The gained solid suspension is in 150ml95% ethanol, and stirring at room 2 hours is used saturated NaHCO
3Neutralization solution continues to stir 1 hour to alkalescence, suction filtration, and with a small amount of absolute ethanol washing filter cake, bullion gets needle crystal 29.09 grams, yield 76.4% through ethanol/water mixed solvent (1:1) recrystallization.
1HNMR(CDCl
3)：8.00(2H，d，J＝9.0Hz，Ar-H)，7.81(2H，d，J＝8.1Hz，Ar-H)，7.42(2H，d，J＝8.1Hz，Ar-H)，7.23-7.36(5H，m，Ar-H)，6.52(2H，d，J＝8.7Hz，Ar-H)，5.08(1H，t，J＝6.3Hz，CH)，3.49(2H，d，J＝6.0Hz，CH
2)；MS(FAB)：382(M+H)。
Synthesizing of 3-phenyl-3-(4-oil of mirbane amido)-1-(4-bromophenyl)-1-acetone (MWW6015)
Phenyl aldehyde 10.60 grams (0.1mol), 4-N-methyl-p-nitroaniline 13.81 grams (0.1mol), absolute ethyl alcohol 150ml are added in the reaction flask; After the stirring at room 10 minutes; Add the concentrated hydrochloric acid of 4-bromoacetophenone 19.91 grams (0.1mol) and catalytic amount, the stirring at room reaction is 20 hours then.After reaction finishes, with the reaction solution cool overnight, the solid that suction filtration is separated out, and use absolute ethanol washing.The gained solid suspension is in 150ml95% ethanol, and stirring at room 2 hours is used saturated NaHCO
3Neutralization solution continues to stir 1 hour to alkalescence, suction filtration, and with a small amount of absolute ethanol washing filter cake, bullion gets needle crystal 30.66 grams, yield 72.1% through ethanol/water mixed solvent (1:1) recrystallization.
1HNMR(CDCl
3)：8.00(2H，d，J＝9.3Hz，Ar-H)，7.73(2H，d，J＝8.4Hz，Ar-H)，7.58(2H，d，J＝8.4Hz，Ar-H)，7.23-7.39(5H，m，Ar-H)，6.52(2H，d，J＝9.3Hz，Ar-H)，5.09(1H，t，J＝6.0Hz，CH)，3.49(2H，d，J＝7.2Hz，CH
2)；MS(FAB)：426(M+H)。
Biological activity test
1. material installation
1.1 plasmid and cell strain: expression of androgen receptor plasmid and luciferase reporter gene plasmid are made up by The National Center for Drug Screening; Human cervical carcinoma's epithelial cell strain HeLa, human breast cancer cell strain MDA-MB-453 and Human Prostate Cancer Cells strain LNCaP are all available from U.S. ATCC.
1.2 reagent: foetal calf serum (Fetal bovine serum, FBS, GIBCO/BRL, USA); Gac and VISOSE processing foetal calf serum (CD-FBS, Hyclone, USA); DMEM and RPMI1640 substratum (GIBCO/BRL, USA); The IMEM substratum (Bioresource, USA), the luciferase detection kit (Promega Corporation, USA); Fugene6 (Roche Ltd., USA); [
3H] and androstanediol (Dehydrotestosterone, DHT, Amersham, UK); Scintillation solution (SuperMixTM, PerkinElmer, USA); Androgen receptor protein is the expression product of this receptor gene in insect cell.
1.3 instrument: Envision2101Multilabel Reader (PerkinElmer, USA); CO2gas incubator (Forma, USA); Wallac
TriLux1450 (PerkinElmer, USA); VERSA
MaxMicroplate Reader (Molecular Devices, USA).
2. experimental technique and result
2.1 receptors bind vigor test
With the DHT shown in the DMSO preparation table 1 and the gradient solution of each compound of the present invention; DHT concentration is followed successively by 0,0.3,1,3,10,30,100nM; Compound concentration is followed successively by 0,0.128,0.64,3.2,16,80,400,2000nM, adds respectively in each gradient DHT of 5 μ l or each hole of testing compound solution to comb.Androgen receptor protein is added damping fluid [the 25mM NaPO4 that is furnished with 1 μ g/ μ l Trypsin inhibitor,Trasylol (Aprotinin) and leupeptin proteinase inhibitor such as (Leupeptin) in advance; 10% glycerine (Glycerol), 10mM NaMoO4,10mM KF; PH7.5] in, add final concentration and be 5nM [
3H] DHT, fully behind the mixing, the amount by every hole 195 μ l adds in the comb 4 ℃ of incubated overnight rapidly.Hatch finish after, in the every hole of comb, add 50 μ l Win 40350 (HA) solution (25%, 25mM Na3PO4, pH=7.4), the concussion mixing was hatched 10 minutes, concussion in per therebetween three minutes once.Centrifugal 3 minutes of 2500rpm siphons away supernatant, keeps deposition.Every hole adds the above-mentioned damping fluid of 200 μ l, avoids the vibration deposition, recentrifuge 3 minutes as far as possible.Siphon away supernatant; Keep deposition, repeated centrifugation 1 time siphons away supernatant; Keep deposition; Every hole adds 300 μ l scintillation solutions, and the concussion mixing is with Wallac
TriLux1450 reading.Two compounds are suitable with positive drug DHT to the avidity of androgen receptor, its IC
50Value is less than 10nM (seeing Fig. 1, table 1).
Table 1 compound is to the combination vigor test of androgen receptor
2.2 cytotoxicity experiment
The HeLa cell cultures is waited to grow to 90% and is merged, with adding 96 orifice plates with 4000/ hole after the trysinization, 37 ℃ of overnight cultures in the RPMI1640 substratum that contains 10%FBS and 2mM L type glutaminate (L-glutamine).Testing compound is added cell with finite concentration dilution back, and the concentration of compound MWW6003 and MWW6015 is followed successively by 0,2.56, and 12.8; 64.0,320,1600; 8000,40000nM adds MTT solution (5mg/mL) behind the cultivation 68h; The 560nm absorbance value is surveyed in 20 μ L/ holes, and reference wavelength is 690nM.Experimental result shows that compound MWW6003 and MWW6015 only have low cytotoxicity, the IC of MWW6003 to the HeLa cell
50Value is 2.8 μ M, the IC of MWW6015
50Value is (see figure 2) between 10～40 μ M.
2.3 reporter gene expression detects
The MDA-MB-453 cell cultures is in the IMEM substratum that contains 10%FBS and 2mM L type glutaminate (L-glutamine).Transfection changes the IMEM substratum that contains 5%CD-FBS into previous day, and Fugene6 reagent is adopted in transfection.Reporter gene carrier and Fugene6 are evenly dropwise added in the cell with the mixed of 1:3, at 37 ℃ and 5%CO
2Cultivated 6 hours under the condition.Insert 96 well culture plates with 20000/100 μ l/ holes behind the cell dissociation, cultivate based on 37 ℃ with the IMEM that contains 5%CD-FBS and cultivated 2 hours.Add testing compound.During the agonist mode detection, DHT, MWW6003 and MWW6015 concentration are followed successively by 0,0.01,0.1,1,10,100,1000,10000nM; (Bicalutamide BCA) is followed successively by 0,0.01,0.1,1,10,100,1000 with compound concentrations to bicalutamide during the antagonism mode detection, and 10000nM adds 2nM DHT simultaneously as agonist in the cell.After hatching 24 hours, use the luciferase detection kit and detect enzymic activity, assess the pharmacologically active of compound androgen receptor with this.Compound MWW6003 and MWW6015 be display part AR agonist activity under activation pattern, and its usefulness is respectively 19.5% and 20.4% of DHT, EC
50Be respectively 320.1nM and 159.6nM, the EC of DHT under the similarity condition
50Be 0.6nM; Compound MWW6003 and MWW6015 have all shown certain AR antagonistic activity, its IC under the antagonism pattern
50Be respectively 884.8 and 958.1nM, and the IC of BCA under the similarity condition
50Be the 690.9nM (see figure 3).
2.4 prostate cancer cell strain propagation detects
The LNCaP cell cultures is in the RPMI1640 substratum that contains 10%FBS and 2mM L type glutaminate (L-glutamine).Experiment changes the RPMI1640 substratum that contains 5%CD-FBS into previous day, waits to grow to 90% and merges, with adding 96 orifice plates with 4000/90 μ L/ hole after the trysinization, 37 ℃ of overnight cultures.Testing compound is added cell with finite concentration dilution back with 10 μ L/ holes, and during the agonist mode detection, DHT, MWW6003 and MWW6015 concentration are followed successively by 0,0.01,0.1,1,10,100,1000,10000nM; BCA and compound concentrations are followed successively by 0,0.01,0.1,1,10,100,1000 during the antagonism mode detection, and 10000nM adds 5nM DHT simultaneously as agonist in the cell.Cultivated 6 days, and changed dressings once in the time of the 3rd day for 37 ℃.Cultivate and finish the preceding MTT solution (5mg/mL) that adds, the 560nm absorbance value is surveyed, reference wavelength 690nm in 20 μ L/ holes.Experimental data is as shown in Figure 4, and compound MWW6003 and MWW6015 all show certain activity trend (Fig. 4) under the pattern of exciting and antagonism.
3. experiment conclusion
(1) compound MWW6003 and MWW6015 show that combination is active preferably, its IC in the competitive combination vigor test of androgen receptor
50Numerical value is less than 10nM, and is suitable with DHT.
(2) compound MWW6003 and MWW6015 demonstrate low cytotoxicity in the toxicity test of HeLa cell.
(3) compound MWW6003 and MWW6015 show to have androgen receptor excitement/antagonistic activity preferably in MDA-MB-453 cell reporter gene detection method; In the LNCaP proliferation experiment, also shown certain excitement/antagonistic activity trend, pointed out it, the purposes in preventing/treating male sex hormone and androgen-receptor related diseases as androgen modulators.
Claims (3)
1. one type of compound with following general formula I structure or its pharmacy acceptable salt prevent and/or treat symptom that male sex hormone and androgen receptor functional disorder cause or the purposes in the disease medicament as the nonsteroidal androgen receptor agonist in preparation:
Wherein, R is Cl or Br.
2. purposes according to claim 1; It is characterized in that described pharmacy acceptable salt is compound and hydrochloric acid, Hydrogen bromide, nitric acid, sulfuric acid, phosphoric acid, formic acid, acetate, propionic acid, phenylformic acid, toxilic acid, fumaric acid, succsinic acid, tartrate, Hydrocerol A, the alkylsulphonic acid of general formula I structure, the salt of aryl sulfonic acid.
3. claim 1 or 2 described purposes, symptom that wherein said male sex hormone and androgen receptor functional disorder cause or disease comprise that the middle-aging male male sex hormone lacks partly that syndrome, osteoporosis, muscle wasting, femal sexual function are complete, apocleisis, evil matter are sick, alzheimer's disease and parkinsonism.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100392686A CN101284795B (en) | 2007-04-09 | 2007-04-09 | Non-steroidal male hormone receptor regulating agent and medical uses thereof |
| PCT/CN2008/000649 WO2008122198A1 (en) | 2007-04-09 | 2008-03-31 | Non-steroidal androgen acceptor regulators and their medical use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100392686A CN101284795B (en) | 2007-04-09 | 2007-04-09 | Non-steroidal male hormone receptor regulating agent and medical uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101284795A CN101284795A (en) | 2008-10-15 |
| CN101284795B true CN101284795B (en) | 2012-04-25 |
Family
ID=39830472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100392686A Expired - Fee Related CN101284795B (en) | 2007-04-09 | 2007-04-09 | Non-steroidal male hormone receptor regulating agent and medical uses thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101284795B (en) |
| WO (1) | WO2008122198A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101538230B (en) * | 2008-12-30 | 2013-04-03 | 西南大学 | Beta-amino ketones compound with anti-diabetic activity |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6160011A (en) * | 1997-05-30 | 2000-12-12 | The University Of Tennessee Research Corporation | Non-steroidal agonist compounds and their use in male hormone therapy |
| DE60124322T2 (en) * | 2000-08-24 | 2007-05-31 | University Of Tennessee Research Foundation, Knoxville | SELECTIVE MODULATORS OF THE ANDROGEN RECEPTOR AND METHODS OF THEIR USE |
| CN1869002A (en) * | 2005-05-27 | 2006-11-29 | 中国科学院上海药物研究所 | Class I non-steroid androgen acceptor regulator, its preparation method and use |
-
2007
- 2007-04-09 CN CN2007100392686A patent/CN101284795B/en not_active Expired - Fee Related
-
2008
- 2008-03-31 WO PCT/CN2008/000649 patent/WO2008122198A1/en active Application Filing
Non-Patent Citations (2)
| Title |
|---|
| Yi Lin,et al..The Mannich reaction between aromatic ketones,aromatic aldehydes and aromatic amines.《Synthesis》.1991,(第9期),717-718. * |
| YiLin et al..The Mannich reaction between aromatic ketones |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008122198A1 (en) | 2008-10-16 |
| CN101284795A (en) | 2008-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11779550B2 (en) | Bisphenol ether derivatives and methods for using the same | |
| CN100591660C (en) | Non-steroidal androgen receptor modulator and its preparation method, pharmaceutical composition and use | |
| US9365510B2 (en) | Aziridine bisphenol ethers and related compounds and methods for their use | |
| US11345670B2 (en) | Heterocyclic compounds for cancer imaging and treatment and methods for their use | |
| JP6100439B2 (en) | Ester derivatives of androgen receptor modulators and methods for their use | |
| RU2473343C2 (en) | Treating tuberous sclerosis | |
| CN101146535A (en) | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | |
| JP2016530285A (en) | Halogenated compounds for imaging and treatment of cancer and methods of use thereof | |
| JP2009533457A (en) | Nitroxyl donors derived from C-nitroso | |
| TW200300078A (en) | Method of treating disorder related to high cholesterol concentration | |
| KR20240033207A (en) | Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat | |
| CN101284795B (en) | Non-steroidal male hormone receptor regulating agent and medical uses thereof | |
| CN101289408B (en) | Non-steroidal progesterone receptor modulator and its preparation method, pharmaceutical composition and use | |
| JP2022543832A (en) | Estrogen receptor modulators for treating mutants | |
| CN107233340B (en) | Application of aromatic ring medicine in inhibiting key transcription factor of malignant melanoma | |
| CN101677988A (en) | Composition for transdermal or transmucosal administration | |
| US9193711B2 (en) | SERMs for the treatment of estrogen receptor-mediated disorders | |
| JP2001181209A (en) | Use of apo b secretion/mtp inhibitor | |
| JP5986098B2 (en) | Integrin-binding kinase inhibitor | |
| EP2353594A1 (en) | Compositions comprising tramadol and the co-crystal of celecoxib and L-proline in the treatment of pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120425 Termination date: 20130409 |